Clinical Trials Logo

Clinical Trial Summary

This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria. A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis.


Clinical Trial Description

Berubicin is one of the first anthracyclines that crosses the blood brain barrier and overcomes drug resistance (i.e. it is not a substrate for multi-drug resistant/breast cancer resistant transporters). A Phase 1 clinical trial of berubicin in patients with primary CNS malignancies demonstrated a durable response (one subject alive 13+ years) as well as stable disease in heavily pretreated patients. Therefore, this phase 2 study is designed to further evaluate Berubicin's activity in patients with rGBM after treatment with standard of care. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04762069
Study type Interventional
Source CNS Pharmaceuticals, Inc.
Contact
Status Active, not recruiting
Phase Phase 2
Start date May 18, 2021
Completion date March 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04869449 - Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas Early Phase 1
Withdrawn NCT03480867 - Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA) Phase 1
Not yet recruiting NCT05653622 - Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma Phase 2
Recruiting NCT05954858 - Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma N/A
Recruiting NCT05052957 - hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) Phase 2
Recruiting NCT05977738 - Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin Early Phase 1
Recruiting NCT04614909 - Study of Pamiparib in Newly Diagnosed and rGBM Early Phase 1
Recruiting NCT06146738 - The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
Recruiting NCT06146725 - The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
Recruiting NCT06283927 - The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Recruiting NCT06118723 - The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Recruiting NCT04825275 - Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial Early Phase 1
Recruiting NCT05333588 - The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme. Early Phase 1
Recruiting NCT05565521 - UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly Phase 2
Completed NCT05671016 - Brain Imaging to Predict Toxicity in Elderly Patients After Radiotherapy
Recruiting NCT05271240 - Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM Phase 3
Recruiting NCT04469699 - Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma Phase 2
Recruiting NCT05720078 - UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3) N/A